Stocktoria
Coherus Oncology, Inc. CHRS
Coherus Oncology, Inc. (CHRS) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $42.2M at a 398.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: 2.92 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CHRS | Coherus Oncology, Inc. | 4/9 | — | 1.4 | +59.8% |
| EDIT | Editas Medicine, Inc. | 1/9 | — | — | +25.4% |
| VYGR | Voyager Therapeutics, Inc. | 1/9 | -1.03 | — | -49.5% |
| FENC | FENNEC PHARMACEUTICALS INC. | — | -4.88 | — | -6.1% |
| SGMO | SANGAMO THERAPEUTICS, INC | 2/9 | — | — | -31.6% |
| KYMR | Kymera Therapeutics, Inc. | 3/9 | 9.79 | — | -16.7% |
| CCCC | C4 Therapeutics, Inc. | 3/9 | -2.12 | — | +1% |
About Coherus Oncology, Inc.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
FAQ
Is CHRS financially healthy?
Coherus Oncology, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does CHRS pay a dividend?
No, Coherus Oncology, Inc. does not currently pay a dividend.
How profitable is CHRS?
In FY2025, Coherus Oncology, Inc. had a net margin of 398.4% and a return on equity of 275.4%.
Is CHRS overvalued or undervalued?
Coherus Oncology, Inc. trades at about 0.8× trailing earnings — below its 10-year norm (10-year range 1.5×–14.7×, median 11.6×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for CHRS?
The average Wall-Street price target for Coherus Oncology, Inc. is $7.80, about 566.7% above the recent price, from 5 analysts (consensus: strong buy).
Is CHRS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Coherus Oncology, Inc.: a Piotroski F-score of 4/9, a P/E of about 1.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.